MedTrace Logo

S0511, Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer

NCT00217659 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-01-03

No results posted yet for this study

Summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using goserelin and anastrozole may fight breast cancer by blocking the use of estrogen by the tumor cells. Giving goserelin together with anastrozole may be an effective treatment for male breast cancer.

PURPOSE: This phase II trial is studying how well giving goserelin together with anastrozole works in treating men with recurrent or metastatic breast cancer.

Conditions

Interventions

DRUG

anastrozole

DRUG

goserelin acetate

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • SWOG Cancer Research Network

    lead NETWORK

Principal Investigators

  • Zeina Nahleh, MD · Barrett Cancer Center

  • Abdul-Rahman Jazieh, MD, MPH · Barrett Cancer Center

  • Robert B. Livingston, MD · University of Washington

  • Gabriel N. Hortobagyi, MD, FACP · M.D. Anderson Cancer Center

Study Design

Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2007-01-31
Completion
2007-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00217659 on ClinicalTrials.gov